Shirt a Phobia

Sample Page

MDMAI, also known as 5,6-methylenedioxy-N-methyl-2-aminoindane, is a drug of the 2-aminoindane family developed in the 1990s by a team led by David E. Nichols at Purdue University.[1][2] It acts as a non-neurotoxic serotonin releasing agent (SRA) in animals and is a putative entactogen in humans.[1][2]

Interactions

See also: MDMA § Interactions

History

MDMAI was first described in the scientific literature by David E. Nichols and colleagues in 1990.[1][2]

Chemistry

MDMAI can be thought of as a cyclized analogue of MDMA where the α-methyl group of the alkylamino side chain has been joined back round to the 6-position of the aromatic ring to form an indane ring system. This changes the core structure of the molecule from phenethylamine to 2-aminoindane, and causes the pharmacological properties of the two compounds to be substantially different.[2]

See also

References

  1. ^ a b c Sainsbury PD, Kicman AT, Archer RP, King LA, Braithwaite RA (2011). “Aminoindanes–the next wave of ‘legal highs’?”. Drug Test Anal. 3 (7–8): 479–482. doi:10.1002/dta.318. PMID 21748859.
  2. ^ a b c d Oberlender R, Nichols DE (1990). “(+)-N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine as a discriminative stimulus in studies of 3,4-methylenedioxy-methamphetamine-like behavioral activity”. J Pharmacol Exp Ther. 255 (3): 1098–1106. doi:10.1016/S0022-3565(25)22947-0. PMID 1979813.